ArticleFrontiers in pharmacology2025
Statins and long-term risk of revision surgery after total hip arthroplasty in osteoarthritis: a multi-source data linkage study.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Perioperative denosumab exposure and risk of revision after total hip and knee arthroplasty in osteoarthritis: a registry-based data linkage study.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Statins, widely used lipid lowering drugs, have been associated with pleiotropic beneficial effects. Notably, studies conducted Methods: We performed a retrospective analysis of patients who underwent THA for OA in the Italian RIPO registry of Emilia-Romagna. Electronic health records were scrutinized to gather information regarding comorbidities and statin prescriptions. We employed propensity score (PS) matching to pair 1:1 statin users (SU) with statin non-users (SNU), considering factors such as age, sex, and the duration of follow-up. Survival of THA was compared between the two groups; secondary analyses were performed to ascertain the role of mortality, sex, indication for statin treatment, and statin potency or lipophilicity. Results: 10,927 patients were classified as SU and PS-matched with SNU. SU showed a reduced risk of THA revision over a 15-year period (adjHR 0.76, 95% CI: 0.67-0.88; p < 0.001). Notably, this observation remained consistent regardless of the indication for statin therapy or the specific characteristics of the statin medications prescribed, and it was more pronounced among male patients (adjHR 0.64, 95% CI: 0.52-0.80, p < 0.001). Conclusion: Our findings suggest that statin treatment is associated with a decreased risk of long-term THA revision in patients with OA, irrespective of the original indication for statin therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.